From GlobeNewswire: 2025-05-01 16:20:00

Shattuck Labs, Inc. reported a cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027. The company is advancing its SL-325 program with an IND filing expected in the third quarter of 2025. SL-325 is a potentially first-in-class DR3 antagonist antibody for the treatment of IBD and other inflammatory diseases.

Shattuck Labs’ lead product candidate, SL-325, is a DR3 blocking antibody expected to enter Phase 1 clinical trials soon. The company plans to nominate a lead bispecific candidate from its preclinical pipeline in 2025. Recent events include participation in industry conferences and the presentation of preclinical studies showcasing SL-325’s favorable safety profile and efficacy.

Financially, as of March 31, 2025, Shattuck Labs had cash and cash equivalents of $60.9 million. Research and development expenses were $9.9 million, and general and administrative expenses were $4.5 million for the first quarter of 2025. The net loss for the quarter was $13.7 million. The company’s cash runway guidance indicates funding operations into 2027.

SL-325 is a potential first-in-class DR3 blocking antibody designed to target the DR3/TL1A pathway. Shattuck Labs specializes in developing treatments for inflammatory and immune-mediated diseases, with a focus on IBD. The company’s expertise in protein engineering underpins its lead program, SL-325, which is expected to have an IND filing in the third quarter of 2025.

Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company working on innovative treatments for inflammatory and immune-mediated diseases. The company’s lead program, SL-325, is a DR3 antagonist antibody with promising potential for treating IBD. Shattuck Labs’ financial results for the first quarter of 2025 show a cash balance of $60.9 million, supporting operations into 2027.



Read more at GlobeNewswire:: Shattuck Labs Reports First Quarter 2025 Financial Results